Le combat pour défendre l’intérêt public, dont font partie la santé, l’environnement et les conditions dignes de travail, doit être mené à chaque fois qu’un traité de commerce international et de protection des investissements est annoncé.

The tobacco industry has a long history of using international trade deals to force their products into new markets.

The Jeju provincial government has revoked the business license of a Chinese-owned for-profit hospital. The Chinese group may file a suit against the Korean government, using the investor-state dispute settlement system.

Philip Morris, a US company, moved ownership of its Australian operations to Hong Kong to take advantage of ISDS in an Australia-Hong Kong investment treaty.

It has taken a second FOI case and another two years to reveal that Australian taxpayers were only awarded half of the costs of defending Australia’s tobacco plain packaging laws against tobacco giant Philip Morris in March 2017.

Free trade agreements like the RCEP will infringe on India’s intellectual property laws. India must stand its ground in the interest of public health.

Ces dernières années marquent l’intérêt grandissant des sociétés pharmaceutiques internationales pour l’arbitrage à l’encontre d’États.

The Korea government may face another investor-state dispute case from the Chinese capital if the license is called off.

Multinational corporations are suing countries for using generic versions of life saving medicines.

The German Supreme Court dismissed the original arbitration decision against Slovakia concerning the ban on health-insurance companies’ profits.